Concomitant i.v. and oral clodronate in the relief of bone pain - A double blind placebo-controlled study in patients with prostate cancer

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 939-942

  Kylmala T ^a   Taube, T ^b   Tammela, T L J ^a   Risteli, L ^c   Risteli, J ^c   Elomaa, I ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Bone metastasis; Clodronate; Oestramustine phosphate; Prostate cancer

Indexed keywords

CLODRONIC ACID; ESTRAMUSTINE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER HORMONE THERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030823523     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.488     Document Type: Article

References (14)

1. Adami S and Mian M (1984) Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Rec Results Cancer Res 116: 67-72
2. Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, Mobilo G and Locascio V (1985) Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134: 1152-1154
3. Cresswell SM, English PJ, Hall RR, Roberts JT and Marsh MM (1995) Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 76: 360-365
4. Elomaa I, Kylmälä T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppänen J and Alftan O (1992) Effect of clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 24: 159-166
5. Kylmàlà T, Tammela T, Risteli L, Risteli J, Taube T and Elomaa I (1993) Evalualion of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of Finnish Prostate Cancer Group. Eur J Cancer 29A: 821-825
6. Kylmälä T, Tammela TLJ, Lindholm TS and Seppänen J (1994) Effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 83: 316-319
7. Melkko J, Niemi S, Risteli L and Risteli J (1990) Radioimmunoassy for carboxyterminal propeptide of human type I procollagen (PICP). Clin Chem 36: 1328-1332
8. Risteli J, Elomaa I, Niemi S, Novamo A and Risteli L (1993) Radioimmunassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 635-640
9. Robertson AG, Reed NS and Ralston SH (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13: 2427-2430
10. Schmidt JD, Johnson DE, Scott WW, Gibbons RB, Prout GR and Murphy GP (1976) The National Prostate Cancer Project. Chemotherapy of advanced prostatic cancer: evaluation of response parameters. Urology 7: 602
11. Soloway MS, Hardenun SW, Hickey D, Raymond J, Todd B, Soloway S and Moinuddin M (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202
12. Taube T, Kylmälä T, Lamberg-Allardt C, Tammela TLJ and Elomaa I (1993) The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a douhle-blind randomised placebo-controlled study. Eur J Cancer 30A: 751-758
13. Vorreuther R (1993) Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 72: 792-795
14. Vorreuther R, Klotz TH and Engelking R (1992) Clodronat in der palliativen Therapie des ossär metastasierten Prostatakarzinoms. Urologe 31: 63-66